Cognitive effects of the acetylcholinesterase inhibitor, donepezil, in healthy, non-treatment seeking smokers: a pilot feasibility study by Ashare Rebecca L, Ray Riju, Lerman Caryn, Strasser Andrew A in Drug and alcohol dependence (2012). PubMed

Abstract

There is a need to identify medications to aid in smoking cessation. Reducing withdrawal-related cognitive deficits represents a pharmacological target for new pharmacotherapies. Endogenous acetylcholine levels, which are modulated by acetylcholinesterase inhibitors (AChEIs), play an important role in smoking behavior and cognition. This pilot feasibility study tested whether an AChEI, donepezil, enhanced cognitive performance among healthy smokers.

[ hide abstract ]

Discussed In Paper

Related In Paper

Variant Annotations

None.